康惠製藥(603139.SH):實控人將變更為李紅明、王雪芳夫婦
格隆匯3月20日丨康惠製藥(603139.SH)公佈,2025年3月20日,公司控股股東康惠控股與悦合智創簽署了《股份轉讓協議》,康惠控股擬向悦合智創協議轉讓其持有上市公司2197.36萬股股份(占上市公司股份總數的22%),轉讓價格為人民幣24.70元/股,標的股份轉讓總價款為人民幣5.43億元。上述股份不存在質押、凍結等受限情況。
本次權益變動完成後,康惠控股持有上市公司1473.26萬股股份,占上市公司總股份數的14.75%,康惠控股與王延嶺合計持有上市公司2138.26萬股股份,合計占上市公司總股份數的21.41%。
另外,根據《股權轉讓協議》約定,為保持交易完成後上市公司控制權的穩定性,轉讓方同意,康惠控股、王延嶺將出具有關表決權放棄的書面文件,承諾自交割日起合計放棄其所持有的上市公司10%股份所對應的表決權。同時,轉讓方同意,康惠控股、王延嶺在交割日後且在表決權放棄期間內不得與其他第三方股東簽署構成一致行動關係的協議。
放棄表決權後,康惠控股、王延嶺持有具有表決權的股份數量為1139.46萬股,占上市公司總股份數的11.41%。康惠控股將不再是上市公司的控股股東,上市公司的控股股東將變更為悦合智創,實際控制人將變更為李紅明、王雪芳夫婦。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.